Genetic and epigenetic alterations at secondary resistance after continued decitabine-based treatment of acute myeloid leukemia in the randomized phase II DECIDER trial.

IF 13.4 1区医学 Q1 HEMATOLOGY

Leukemia Pub Date : 2025-10-07 DOI:10.1038/s41375-025-02780-7

Inga Hund,Maria Elena Hess,Geoffroy Andrieux,Julia Stomper,Gabriele Greve,Christoph Niemöller,Tobias Ma,David Uhl,Olga Grishina,Felicitas Thol,Michael Heuser,Gesine Bug,Martina Crysandt,Andreas Neubauer,Justus Duyster,Hartmut Döhner,Melanie Boerries,Michael Lübbert,Heiko Becker

引用次数: 0

查看原文本刊更多论文

在随机II期DECIDER试验中，持续地西他滨治疗急性髓系白血病后继发耐药的遗传和表观遗传改变。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Leukemia 医学-血液学

CiteScore

18.10

自引率

3.50%

发文量

270

审稿时长

3-6 weeks

期刊介绍： Title: Leukemia Journal Overview: Publishes high-quality, peer-reviewed research Covers all aspects of research and treatment of leukemia and allied diseases Includes studies of normal hemopoiesis due to comparative relevance Topics of Interest: Oncogenes Growth factors Stem cells Leukemia genomics Cell cycle Signal transduction Molecular targets for therapy And more Content Types: Original research articles Reviews Letters Correspondence Comments elaborating on significant advances and covering topical issues